Genexine, Inc.

Postech Academy-industry Foundation

Postech Foundation

Genexine Co., Ltd.

Gi Innovation, Inc.

Posco

The Green Cross Corporation

Korea Greencross Corporation

Dong-a Pharm. Co., Ltd.

Msd International Gmbh

Phi Biomed Co., Ltd.

Progen Co., Ltd.

Biod Co., Ltd.

Daewoong Pharmaceutical Co., Ltd.

Dong-a Pharmaceutical Co., Ltd

Young Chul Sung

Sehwan Yang

Sang Hwan Seo

Donghoon Choi

Sang Hoon Park

Zungyoon Yang

Moon Cheol Kang

Young Woo Choi

Sung Hee Lee

Se Hwan Yang

You Suk Suh

Hyun Tak Jin

Jun Chang

Sang Jun Ha

Su Jin Kim

Keon Jae Lee

Min Woo Kim

Sei Kwang Hahn

Myung Ho Jang

Myoung Ho Jang

Won Bae Kim

Su-hyung Park

Man Ki Song

Je-In Youn

In Chul Park

Jung Won Woo

Seung Kew Yoon

Beom Ho Mun

Dohee Keum

Hee Sup Shin

Eun Kyoung Choi

Jung-Won Woo

Jong Sup Park

Jin Won Youn

Seok Il Hong

Sun Sim Choi

Eun Ju Shin

Mi Sun Byun

Sang In Yang

Ki Seok Park

Jin-Won Youn

Se-Hwan Yang

Chang Geun Lee

Sang-In Yang

Doo Hong Park

Jin Won Yun

Sae Won Kim

Jong Moon Son

Byung Moon Kim

Se Jin Im

Su Hyung Park

The present invention provides a polypeptide dimeric protein containing two monomers, each of which contains an extracellular domain (FcεRIa-ECD) of an alpha subunit of an IgE Fc receptor. The dimeric protein according to the present invention has advantages that an excellent binding ability to IgE is exhibited as compared with a conventional therapeutic agent containing an anti-IgE antibody, and less other side effects are exhibited due to lack of ADCC and CDC functions. Thus, the dimeric protein can be applied to a medical product for treating or preventing an IgE-mediated allergic disease.

Extracellular domain of alpha subunit of IgE Fc receptor, pharmaceutical composition comprising same and method for producing same

The present invention relates to a pharmaceutical composition comprising an interleukin-7 fusion protein to which an immunoglobulin Fc region has been fused for preventing or treating diseases caused by influenza virus A. The fusion protein comprising the immunoglobulin Fc region and IL-7 according to the present invention protects the body from infection due to influenza virus A and thus can treat diseases which can be caused by the virus.

Virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein

A composition containing, as active ingredients, probiotics and a polypeptide with a binding ability to IgE is disclosed. In particular, a synergistic effect of remarkably decreasing food allergy was identified at the time of combined administration of probiotics and a recombinant protein containing an extracellular domain of an alpha subunit of an IgE Fc receptor. Therefore, it is expected that the composition is highly industrially applicable due to being able to exhibit a remarkable therapeutic effect on an IgE-mediated allergic disease as compared with conventional pharmaceutical compositions.

Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof

A treatment of cervical tumor caused by human papillomavirus (HPV) infection is disclosed. Methods for improving cervical tumor treatment and methods for treating cervical tumor caused by HPV infection include administering a combination of a HPV-specific fusion protein and an immunomodulatory agent.

Method for treating cervical cancer

The present invention relates to a pharmaceutical composition comprising an immunoglobulin Fc region and an IL-7 fusion protein. Specifically, when a fusion protein comprising the immunoglobulin Fc region and IL-7 is administered to an affected area, a strong immune response is induced in the body and thus allows human papillomavirus-caused diseases to be prevented or treated.

Pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein for preventing or treating human papillomavirus-caused diseases

The present invention relates to a method for treating anemia using a long-acting EPO formulation, and more specifically, a method for treating patients with anemia by confirmation of safe, long-acting, and optimal effective dosage and usage in administering a fusion polypeptide which comprises an EPO and an immunoglobulin hybrid Fc to patients with anemia. The method of administering the fusion polypeptide employs an appropriate dosage and usage which not only shows an excellent long-acting property compared to the existing EPO products but also minimizes cardiovascular side effects that may occur due to a rapid increase in hemoglobin level, which is an effect of anemia treatment.

Method of treating anemia using long-acting EPO formulation

Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin Fc-fused interleukin-7 fusion protein

The present invention relates to a composition for the diagnosis and treatment of recurrent thyroid cancer comprising recombinant human thyroid stimulating hormone (rhTSH) and a method for producing the recombinant human thyroid hormone. The method for producing recombinant human thyroid hormone according to the present invention can effectively produce rhTSH despite being cultured through fed-batch culture, and has a high purification yield and purity. Therefore, the recombinant thyroid stimulating hormone produced by the method can be usefully used for the diagnosis or treatment of recurrent thyroid cancer.

Composition comprising recombinant human thyroid stimulating hormone and method for producing recombinant human thyroid stimulating hormone

The present invention relates to a fusion polypeptide containing a glucagon-like peptide (GLP) and an immunoglobulin hybrid Fc, and more specifically, to a fusion polypeptide with an increased half-life and improved efficacy compared to the conventional fusion polypeptide based on the discovery of an immunoglobulin hybrid Fc suitable for GLP or analogs thereof, and a pharmaceutical composition for treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, containing the fusion polypeptide. The fusion polypeptide of the present invention has an increased half-life and improved resistance to DPP-4 enzyme compared to those of GLP-1 and GLP-2, and it thus has improved drug efficacy in treating diabetes, inflammatory bowel disease, endoenteritis or diarrhea caused by anticancer chemotherapy, or short bowel syndrome, compared to those of the conventional drugs. Accordingly, the fusion polypeptide of the present invention can be effectively applied to pharmaceutical drugs.

Fusion polypeptide containing GLP and immunoglobulin hybrid Fc and use thereof

The present invention provides a smart contact lens including a sensor capable of non-invasively sensing an eye disease in real time and a drug reservoir, and smart glasses for controlling the smart contact lens.

Smart contact lenses and smart glasses

The present invention relates to a fusion protein comprising a fusion polypeptide of E6 and E7 of a human papilloma virus, a signal peptide for secreting the polypeptide out of the cell, and an immune enhancing peptide for a subject; a polynucleotide encoding the fusion protein; and a vector containing the polynucleotide. The present invention further relates to a pharmaceutical composition comprising the fusion protein or the vector; and a method for treating a disease caused by a human papilloma virus using the pharmaceutical composition.

Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer

A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.

Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer

The present invention relates to an intracellular viral vector delivery method employing an iron ion/viral vector composite. The iron ion/viral vector composite according to the present invention is not dependent on the expression of CAR and so improves the efficiency of delivery of viral vectors and gene expression in cells of diverse types, and has an outstanding virus-neutralizing antibody escape performance, exhibits little cytotoxicity and is outstandingly stable even when subjected to iron ion processing at low concentration, and hence can be used to advantage in recombinant viral vaccine compositions.

Intracellular viral vector delivery method employing iron ion/viral vector composite

Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

Chimeric immunoglobulin fusion proteins

Growing community of inventors

Pohang-si, South Korea

Young Chul Sung